TY - JOUR AU - Yonghua Li, AU - Jian Hou, AU - Hua Jiang, AU - Dongxing Wang, AU - Weijun Fu, AU - Zhengang Yuan, AU - Yubao Chen, AU - Lili Zhou, PY - 2007/09/01 Y2 - 2024/03/29 TI - Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide-based regimens in multiple myeloma JF - Haematologica JA - haematol VL - 92 IS - 9 SE - Articles DO - 10.3324/haematol.11319 UR - https://haematologica.org/article/view/4567 SP - 1246-1249 AB - In this study, CYP2C19 genotypes were tested by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in 92 patients with multiple myeloma (MM). Sixty-two patients were treated with thalidomide plus dexamethasone (Thal+Dex) and 30 with thalidomide combined with chemotherapy (Thal+CC). The overall response rate of extensive metabolizers (EMs) was statistically higher than that of poor metabolizers (PMs) (62.6% vs. 33.3%, p